Home World News Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer World News Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 234 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 8, 2020 Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... June 8, 2021 Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,... June 7, 2019 Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... November 8, 2024 Load more HOT NEWS Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients... Tumor Signatures May Help Explain Global Differences in Kidney Cancer Rates Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research Breast Cancer Patients With Anxiety or Depression More Prone to Opioid...
